Quest Diagnostics Lifts 2026 Revenue Outlook To $12.065 Billion–$12.105 Billion As Test Orders Climb 14.5%

Third-quarter revenue rose 10.0% to $3.10 billion, and adjusted earnings guidance moved up to $11.25 to $11.35 a share.

Share
Quest Diagnostics Lifts 2026 Revenue Outlook To $12.065 Billion–$12.105 Billion As Test Orders Climb 14.5%

Quest Diagnostics raised its 2026 outlook after a third quarter in which revenue rose 10.0% to $3.10 billion, according to the earnings release attached to an 8-K filed Thursday. Growth came from more patient test orders, not higher prices per order.

What the results show

Requisition volume, the count of patient test orders, rose 14.5% in the quarter. Revenue per requisition fell 4.2%, so volume carried the growth.

Adjusted diluted earnings per share were $3.00, up 15.4% from a year earlier. Reported diluted EPS was $2.78, up 28.7%.

Operating income was $479 million, up 24.2%. Reported operating margin widened to 15.5% from 13.7%. On an adjusted basis, operating income was $517 million and the margin was 16.7%, versus 16.3%.

Cash provided by operations was $611 million, up 8.8%, against capital spending of $166 million. For the first nine months, operating cash flow was $1,486 million, up from $1,421 million.

The raised guidance

Quest now expects full-year revenue of $12.065 billion to $12.105 billion, up from a prior range of $11.95 billion to $12.05 billion.

Adjusted EPS guidance rose to $11.25 to $11.35, from $11.05 to $11.25. Reported diluted EPS is now expected at $10.21 to $10.31, versus $9.97 to $10.17 before.

Cash from operations is now expected at about $1.90 billion, from about $1.80 billion. Capital spending is unchanged at about $550 million.

CEO Jim Davis credited strength across physician, hospital and consumer channels, plus productivity gains from automation and AI. He said the results show the company is meeting the needs of "an aging population as well as the increasing number of people focused on prevention and wellness."

What to watch

Quest said it advanced Project Nova to its solutions-build phase and still expects to deploy Epic software in its first lab in the fall of 2027. It will hold its 2027 Investor Day on March 25, 2027, at the New York Stock Exchange.

The stock closed at $238.93 on Wednesday, before the results came out.

The next dated event is the March 25, 2027 Investor Day, with the Epic rollout at its first Project Nova lab slated for the fall of 2027.

Sources

More on Quest Diagnostics

All Quest Diagnostics (DGX) coverage →